Loading…
← CockpitCompetitor Analysis › URGN UroGen Pharma Ltd.Open in the cockpit ↗

UroGen Pharma Ltd.URGNCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops and sells non-surgical treatments for urothelial (bladder) cancers using a proprietary reverse-thermal gel.

Momentum weak 25
Mkt cap
$1.46B
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$45.2M
20-day average traded
Fwd P/E
16.7×
forward earnings
ROIC−WACC
n/a
WACC 12.6%
Hurdle
n/a
no reverse DCF
Next earnings
120 days
18 Mar 2027
Close · USD$29.79
1D-0.3%
1W+14.1%
1M-14.9%
3M-36.4%
6M-1.4%
YTD+27.2%
1Y+25.7%
ATR %7.8%
Beta1.16
52w lowhigh41.4% off high

What UroGen Pharma does

Develops and sells non-surgical treatments for urothelial (bladder) cancers using a proprietary reverse-thermal gel.

Sells through specialty distributors to urology practices and hospitals, which are reimbursed by Medicare and insurers, so reimbursement coding matters. Jelmyto, approved in 2020, carries sales; Zusduri, aimed at a larger group of bladder-cancer patients, is the second product.

Products and services

  • Jelmyto (low-grade upper tract urothelial cancer)
  • Zusduri/UGN-102 (bladder cancer)

Customers

  • Urologists/oncologists

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Urologic oncology therapeutics

What could go right

  • UGN-102 commercial launch
  • Growing non-surgical treatment adoption

What could go wrong

  • Reimbursement and adoption pace
  • Competitive bladder cancer treatment landscape

Moat: narrow (IP / patents, regulatory licence). Proprietary sustained-release gel formulation applied to an underserved non-surgical bladder cancer niche.

Headquarters: Princeton, New Jersey, US · Founded: 2004 · Employees: 291

Named competitors

UroGen Pharma at a glance

Size UroGen Pharma (URGN) is a United States Health Care company (Biotechnology) with a market value of $1.46B, the 1987th largest of 3,085 United States companies the cockpit tracks. Shares closed at $29.79 on 18 Nov 2026.

Performance Over six months the shares fell 1.4%, against -17.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 159.3% over the last twelve months (peer median +24.8%); the operating margin is -12.4% (peer median -56.7%).

Valuation It trades at 16.7× forward earnings against a peer median of 46.4× (3rd cheapest of 6).

Short interest Short interest is 10.4% of the free float (30 Oct 2026).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026URGN 100Peer median 82
Six months, rebased to 100: UroGen Pharma against the median of its 20 peers (local-currency closes).

UroGen Pharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$250M$110M$90.4M$82.7M$64.4M
Revenue growth—+21%+9%+29%—
Gross profit$229M$97.3M$81.5M$73.4M$56.7M
EBITDA-$28.2M-$122M-$95.6M-$63.8M-$77.2M
Net income-$65.8M-$153M-$127M-$102M-$110M
Free cash flow-$137M-$163M-$97.1M-$76.6M-$87.8M
Capital expenditure$208,776$289,000$295,000$194,000$254,000
Total debt$196M$130M$125M$100M$100M

Quarterly statements and history in the cockpit →

UroGen Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-50%0%+50%6887652637MSBIMCR087010688105ABSIKRSAANABPGENRAPPNRIX6881854588URGN6-month return →1-month return →
Up and to the right = strong over both horizons. UroGen Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×100×200×2637688105ANABPGEN688185URGNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. UroGen Pharma is the large dot.

UroGen Pharma competitors and peer comparison

Head to head with its named competitors (URGN vs MRK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
UroGen Pharma URGN$1.46B-1%+159%-12%16.7×n/a
Merck & MRK$340B+23%+5%18%16.4×8.3%

How UroGen Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

UroGen Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureURGNPeer medianRank in peer set
1-month return-14.9%-12.7%9th lowest of 21
6-month return-1.4%-17.0%8th highest of 20
Distance from 52-week high-41.4%-45.9%8th highest of 21
Revenue growth (TTM)+159.3%+24.8%6th highest of 18
Operating margin-12.4%-56.7%9th highest of 19
Forward P/E16.7×46.4×3rd cheapest of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%16.7×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%n/an/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%46.4×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%n/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%137.8×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%n/an/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%n/an/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%n/an/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%n/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%4.9×0.5%+25.6%
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%7.3×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%n/an/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%n/an/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%199.3×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%n/an/an/a

Questions

Who are UroGen Pharma's main competitors?
Named competitors: Merck (Keytruda in bladder cancer) (MRK), Ferring Pharmaceuticals (private or unlisted). The cockpit's measured peer set (industry) also includes Wuhan Healthgen Biotechnology (688765.SS), Fujian Haixi Pharmaceuticals (2637.HK), Mesoblast (MSB.AX), Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh (IMCR), Peptron (087010.KS), Nanjing Vazyme Biotech (688105.SS).
Is UroGen Pharma expensive compared with its peers?
On forward p/e it trades at 16.7× against a peer median of 46.4×, 3rd cheapest of 6 in its peer set.
How has UroGen Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -1.4% against -17.0% for the median peer; over one year +25.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.